The therapeutic window: timing dentoalveolar surgery to minimize MRONJ risk in denosumab-treated osteoporotic patients.

JBMR Plus · 2026 · PMC13050504 · PMID 41943819

Europe PMC DOI

hedged sentences

0.0670

closest p · 1.3× alpha

0.0670

boldest claim

The sentences

showed a trendp = .067so close (0.05 < p ≤ 0.1)

did not reach statistical significanceno p-value reported

Although age showed a trend toward an association with MRONJ (OR 1.09, 95% CI: 0.99-1.20, p = .067), it did not reach statistical significance in this model.

also in 35,913 other papers

borderline significantno p-value reported

Both the duration of ARD intake (OR 1.19, 95% CI: 1.05-1.36, p = .0077) and age (OR 1.07, 95% CI: 1.00-1.14, p = .0525) also showed significant or borderline significant associations.

also in 7,848 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.